The latest survey of British Coatings Federation (BCF) members reveals UK coatings manufacturers are increasingly concerned about the effects of the new UK chemical regulations. Almost 80% of respondents believe UK REACH will impact negatively on their businesses, with the fear that there will be a significant reduction in the portfolio of available chemical substances in the UK compared to the EU, and 67% of respondents fear higher costs in the future where suppliers pass on the costs of complying with UK REACH. Worryingly, 19% of respondents are already reporting that EU suppliers no longer want to export to the UK.
The survey also reports challenges for the sector’s UK exporters – 60% fear that having to abide by EU REACH and CLP rules as a ‘third country’ will impact on their business competitiveness, and more than four in ten respondents (43%) reported increased operating costs of more than 5%, with one in ten (9%) citing a figure of more than 10%. These additional cost estimates have increased considerably since the last BCF Brexit Impact Survey at the end of January. On top of these non-tariff costs, the majority of BCF members are still encountering delays to shipping between UK and the EU, and between GB and NI. Overall, after experiencing nearly six months of the new UK-EU trading relationship, half of respondents are still concerned they risk losing EU export customers, and more than a third now worry about their competitiveness compared to EU counterparts as a result of the Trade and Co-operation Agreement (TCA) trading terms. 70% of coatings companies believe their trade with the EU, the sector’s main export market, will reduce, and only 20% see opportunities with the rest of the world from new trade deals.
Tom Bowtell, CEO of the British Coatings Federation, said: “Our latest survey results show that the added complexity of the new UK chemicals regulations is starting to bite. We have consistently called for UK REACH legislation to be amended to avoid the significant additional costs it will bring to business, as well as its potentially devastating impact on raw material availability to our manufacturers in the UK. Failure to amend UK REACH will lead to our coatings members – and other businesses in similar sectors – seeing unsustainable added complexities and extra costs. Exports of chemical-based products from the UK will be severely threatened by UK REACH, as will foreign direct investment into UK factories, as many companies choose to reduce their manufacturing footprint in the UK and relocate to the EU. Overall, the UK will become a less competitive country to do business in.”
“We welcome the fact that Defra has been engaging with industry on the future of UK REACH over the past few months and hope that, even at this late stage, UK REACH can be amended so that it is less damaging to UK businesses.”
A newly developed drug stabilizes dopamine and serotonin levels using a novel mechanism. It effectively treats psychosis in patients with schizophrenia, and researchers are testing its efficacy for Parkinson’s disease as well.
The threat of antibiotic resistance rises as bacteria continue to evolve to foil even the most powerful modern drug treatments. By 2050, antibiotic resistant-bacteria threaten to claim more than 10 million lives as existing therapies prove ineffective.
According to the World Health Organization, about 785 million people around the world lack a clean source of drinking water. Despite the vast amount of water on Earth, most of it is seawater and freshwater accounts for only about 2.5% of the total. One of the ways to provide clean drinking water is to desalinate seawater. The Korea Institute of Civil Engineering and Building Technology (KICT) has announced the development of a stable performance electrospun nanofiber membrane to turn seawater into drinking water by membrane distillation process.
Clariant, a focused, sustainable and innovative speciality chemical company, has reached definitive agreements for the divestment of its Pigments business to a consortium of Heubach Group (“Heubach”) and SK Capital Partners (“SK Capital”)
Shipping costs have risen sharply and fierce competition for ocean freight capacity is the new normal. With new capacity only slowly coming onstream, freight rates are expected to continue to reach new highs this year and will remain above their pre-pandemic levels in the longer term.
AstraZeneca and MSD’s Lynparza (olaparib) has shown efficacy in preventing cancer recurrence in patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Ammonia saved the world once; it might do it again. A century ago, the world faced a looming food crisis. A booming population was pushing farmers to grow crops faster than nitrogen-fixing bacteria in the soil could keep up, and the South American deposits of guano and natural nitrates they applied as fertilizer were dwindling.
Lipids are an unsung component in the two mRNA-based shots, the only vaccines to be approved so far in the US. Naked mRNA quickly degrades in the body and can trigger an unwanted immune reaction. To get the genetic material to its target cells, vaccine developers combine it with a mixture of several sophisticated lipids to form lipid nanoparticles, or LNPs. mRNA vaccine producers use a package of 4 lipids to formulate their LNPs
An unprecedented push to manufacture billions of doses this year alone has led to supply bottlenecks, putting firms such as Pfizer and AstraZeneca Plc in the firing line of angry government customers. Now the industry is taking heat for closely guarding its intellectual property.